Corvus Pharmaceuticals Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - Chief Financial Officer Richard Miller - Chief Executive Officer Conference Call Participants Li Watsek - Cantor Jiale Song - Jefferies Aydin Huseynov - Ladenburg Graig Suvannavejh - Mizuho Jeff Jones - Oppenheimer Operator Good afternoon, everyone, and thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2024 Business Update and Financial Results Conference Call. At this time participants are in a listen-only mode.
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.
Corvus Pharmaceuticals Eyes Phase 3 Trials: Soquelitinib's Promise In PTCL
Corvus Pharmaceuticals' lead candidate, Soquelitinib, is advancing towards a Phase 3 trial for PTCL, set to begin in September 2024. Soquelitinib has shown a 26% Complete Response Rate [CRR] in early trials, more than double the current standard of care. The PTCL market, estimated at $500 million in the U.S., offers significant potential if Soquelitinib's Phase 3 trials are successful.
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2024 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Richard Miller - Chief Executive Officer Leiv Lea - Chief Financial Officer Jeff Arcara - Chief Business Officer Jim Rosenbaum - Senior Vice President, Research Ben Jones - Senior Vice President, Regulatory and Pharmaceutical Sciences Conference Call Participants Li Watsek - Cantor Roger Song - Jefferies Aydin Huseynov - Ladenberg Jeff Jones - Oppenheimer Graig Suvannavejh - Mizuho Operator Good afternoon, everyone, and thank you for standing by. Welcome to the Corvus Pharmaceuticals Second Quarter 2024 Business Update and Financial Results Conference Call.
Corvus Pharmaceuticals Is Ready To Take Flight
Corvus Pharmaceuticals has shown positive growth and maturity over the past six months, with new leadership and increased clinical trial activity. The company is expanding its label and IP developments, with trials in oncology and immunology, as well as potential partnerships with established therapies. Corvus recently completed a capital raise, securing $30M with potential for an additional $60M through warrants, signaling confidence in their Phase 3 trial and future growth.
The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now
One of the best ways to spot opportunities in penny stocks to buy is by following insiders. Most notably, insiders who are putting their money where their mouth is.
